Abbott Laboratories
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Abbott Laboratories (NYSE: ABT) develops, manufactures, and sells a broad range of health care products worldwide. The company operates through four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices; its core offerings include branded generic pharmaceuticals such as Branded generics in emerging markets, anti-infectives, and gastrointestinal drugs; diagnostics encompassing point-of-care testing systems like i-STAT, molecular diagnostics via Alinity platforms, rapid diagnostics under BinaxNOW and Determine brands, and core laboratory instruments; nutritional products including pediatric formulas like Similac and Pediasure, adult nutritionals such as Ensure and Glucerna, and medical foods; as well as medical devices featuring cardiovascular and neuromodulation devices including FreeStyle Libre continuous glucose monitoring systems, Aveir leadless pacemakers, TactiFlex ablation catheters, and structural heart devices like Amplatzer occluders. Abbott serves health care professionals, consumers, hospitals, laboratories, and governments across more than 100 countries, with principal manufacturing facilities in the United States, Europe, Asia, and Latin America. Founded in 1888 and headquartered in Abbott Park, Illinois, the company maintains a diversified portfolio without notable subsidiaries or parent relationships impacting its core structure. In recent developments within the last two years, Abbott completed the acquisition of Cardiovascular Systems, Inc. in 2024 to expand its cardiovascular portfolio; launched the FreeStyle Libre 3 integrated continuous glucose monitoring sensor in multiple markets including the U.S.; introduced the AVEIR DR dual chamber leadless pacemaker system and the TactiFlex Sensor Enabled Ablation Catheter; formed strategic partnerships for digital health integrations and expanded diagnostics manufacturing capacity amid global demand surges; and reported strong growth in its diabetes and cardiovascular segments during 2025 earnings.
What's Backing Abbott's Established Pharmaceuticals Division Growth
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
The U.S. Labor Market Is Weakening. These 2 Dividend Stocks Look Built to Weather a Recession
Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?
AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?
NVST vs. ABT: Which Stock Is the Better Value Option?
Here's How ABT Broadens Diagnostics Growth Base With Oncology Expansion
Abbott Laboratories Lost 16% This Year: One Analyst Sees 35% Gains for the Healthcare Giant
Chelsea Counsel Co. Sells 5,000 Shares of Abbott Laboratories $ABT
Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Bank of America Corp DE Has $1.98 Billion Holdings in Abbott Laboratories $ABT
3 Dividend Stocks to Buy for a Lifetime of Passive Income
These 3 Companies Reported Record Results and Raised Guidance
Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends
Is Abbott Stock Attractive After Its Earnings and Guidance Update?
FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Bank of Nova Scotia Trims Stock Holdings in Abbott Laboratories $ABT